Long-term outcomes of electrical storm patients listed for urgent heart transplantation but not transplanted acutely.

IF 3.2 2区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Miloud Cherbi, Philippe Maury, Léa Benabou, Maxime Faure, Matteo Pozzi, Laurent Sebbag, Estelle Gandjbakhch, Karim Benali, Pierre Groussin, Redwane Rakza, Raphael P Martins, Clément Delmas
{"title":"Long-term outcomes of electrical storm patients listed for urgent heart transplantation but not transplanted acutely.","authors":"Miloud Cherbi, Philippe Maury, Léa Benabou, Maxime Faure, Matteo Pozzi, Laurent Sebbag, Estelle Gandjbakhch, Karim Benali, Pierre Groussin, Redwane Rakza, Raphael P Martins, Clément Delmas","doi":"10.1002/ehf2.15122","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Refractory electrical storm (ES) is a life-threatening condition in which heart transplantation (HTx) can be proposed. Nevertheless, the shortage of donors and subsequent outcomes question its place as a rescue strategy. We aim to describe the prognosis of ES patients listed for HTx but not transplanted.</p><p><strong>Methods and results: </strong>Patients registered on urgent HTx waiting list for refractory ES without being transplanted during initial hospitalization were retrospectively included in five French centres from 2010 to 2022. The primary endpoint was 1-year all-cause mortality. Forty patients were included [90% men; 56.5 (50.0-61.3) years old; 63.6% and 24.2% dilated and ischaemic cardiomyopathies]. Among them, 84.6% received amiodarone, 64.1% received beta-blockers; 50.0% required deep sedation, 35.0% mechanical circulatory support, 10.0% stellate ganglion block; and 57.5% underwent catheter ablation. At 1 year, 20 patients (50.0%) died, including 14 in-hospital deaths (35.0%). Within six patients who died post-discharge, four previously underwent HTx, and one received VAD implantation. Twenty patients (50.0%) were still alive at 1 year: 10 underwent HTx, 1 received VAD implantation followed by subsequent HTx, while another underwent VAD implantation as destination therapy. Finally, five (12.5%) were removed from the HTx waiting list due to functional improvement, distinguished by a median LVEF of 45.0% (20.0%-45.0%). The remaining three patients (7.5%) were still registered on HTx waiting list.</p><p><strong>Conclusions: </strong>Refractory ES is a critical condition with high short- and long-term mortality. While HTx serves as a rescue strategy, rhythm management can sometimes overcome the critical phase, facilitating subsequent HTx under more favourable conditions or even allowing removal from the HTx waiting list.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESC Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ehf2.15122","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Refractory electrical storm (ES) is a life-threatening condition in which heart transplantation (HTx) can be proposed. Nevertheless, the shortage of donors and subsequent outcomes question its place as a rescue strategy. We aim to describe the prognosis of ES patients listed for HTx but not transplanted.

Methods and results: Patients registered on urgent HTx waiting list for refractory ES without being transplanted during initial hospitalization were retrospectively included in five French centres from 2010 to 2022. The primary endpoint was 1-year all-cause mortality. Forty patients were included [90% men; 56.5 (50.0-61.3) years old; 63.6% and 24.2% dilated and ischaemic cardiomyopathies]. Among them, 84.6% received amiodarone, 64.1% received beta-blockers; 50.0% required deep sedation, 35.0% mechanical circulatory support, 10.0% stellate ganglion block; and 57.5% underwent catheter ablation. At 1 year, 20 patients (50.0%) died, including 14 in-hospital deaths (35.0%). Within six patients who died post-discharge, four previously underwent HTx, and one received VAD implantation. Twenty patients (50.0%) were still alive at 1 year: 10 underwent HTx, 1 received VAD implantation followed by subsequent HTx, while another underwent VAD implantation as destination therapy. Finally, five (12.5%) were removed from the HTx waiting list due to functional improvement, distinguished by a median LVEF of 45.0% (20.0%-45.0%). The remaining three patients (7.5%) were still registered on HTx waiting list.

Conclusions: Refractory ES is a critical condition with high short- and long-term mortality. While HTx serves as a rescue strategy, rhythm management can sometimes overcome the critical phase, facilitating subsequent HTx under more favourable conditions or even allowing removal from the HTx waiting list.

目的:难治性电风暴(ES)是一种危及生命的疾病,可建议进行心脏移植(HTx)。然而,供体的短缺和随后的结果对其作为一种抢救策略的地位提出了质疑。我们旨在描述被列入心脏移植名单但未接受移植的 ES 患者的预后情况:我们回顾性地纳入了 2010 年至 2022 年期间法国五个中心因难治性 ES 而登记在紧急 HTx 等待名单上但在最初住院期间未进行移植的患者。主要终点为1年全因死亡率。共纳入40名患者[90%为男性;56.5(50.0-61.3)岁;63.6%为扩张型心肌病,24.2%为缺血性心肌病]。其中,84.6%的患者接受了胺碘酮治疗,64.1%的患者接受了β-受体阻滞剂治疗;50.0%的患者需要深度镇静,35.0%的患者需要机械循环支持,10.0%的患者需要星状神经节阻滞;57.5%的患者接受了导管消融术。1 年后,20 名患者(50.0%)死亡,其中 14 名患者(35.0%)在院内死亡。出院后死亡的 6 名患者中,4 人曾接受过 HTx,1 人接受过 VAD 植入术。20 名患者(50.0%)在 1 年后仍然存活:其中 10 人接受了高温热疗,1 人接受了 VAD 植入术,随后又接受了高温热疗,还有 1 人接受了 VAD 植入术作为终末治疗。最后,有 5 名患者(12.5%)因功能改善而从 HTx 候选名单中除名,他们的中位 LVEF 为 45.0% (20.0%-45.0%)。其余三名患者(7.5%)仍在高温热疗等待名单上:难治性 ES 是一种危重病,短期和长期死亡率都很高。尽管热心切手术是一种抢救策略,但节律管理有时也能克服危重阶段,从而有助于在更有利的条件下进行后续热心切手术,甚至可以从热心切手术等待名单中除名。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ESC Heart Failure
ESC Heart Failure Medicine-Cardiology and Cardiovascular Medicine
CiteScore
7.00
自引率
7.90%
发文量
461
审稿时长
12 weeks
期刊介绍: ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信